title: Evaluation of DepoFoam(®) bupivacaine for the treatment of postsurgical pain.
abstract: SUMMARY An extended-release, multivesicular liposome-encapsulated form of the local anesthetic bupivacaine, DepoFoam(®) bupivacaine (proposed proprietary name EXPAREL™), is in development for use as part of a multimodal regimen for the treatment of postsurgical pain. Placebo- and active-controlled clinical trials in patients who have undergone either orthopedic or soft-tissue procedures indicate that a single local administration into the surgical site results in analgesic activity for up to 3-4 days and decreases the use of opioid rescue medication. The safety profile of DepoFoam bupivacaine appears to be similar to that of bupivacaine HCl, and adverse events are dose-related.
authors.affiliation: Departments of Anesthesiology & Neurological Surgery, Ohio State University Medical Center, 410 W 10th Ave, N411 Doan Hall, Columbus, OH, USA.
authors.forename: Sergio D
authors.initials: SD
authors.lastname: Bergese
authors.forename: Erol
authors.initials: E
authors.lastname: Onel
authors.forename: Juan
authors.initials: J
authors.lastname: Portillo